Screener
Inhibikase Therapeutics, Inc. IKT Q4 2025 Annual earnings
Reported March 26, 2026 · Before market open
EPS-$0.09Beat by $0.03
EPS estimate-$0.12
Next report
Nov 13, 2026 (in 2 months)EPS estimate-$0.11
Versus estimates
Diluted EPS
FAQ
- When did Inhibikase Therapeutics, Inc. report Q4 2025 earnings?
- Inhibikase Therapeutics, Inc. (IKT) reported Q4 2025 earnings on March 26, 2026 before market open.
- What were Inhibikase Therapeutics, Inc.'s Q4 2025 revenue and EPS?
- Inhibikase Therapeutics, Inc. reported eps of $-0.09 for Q4 2025.
- Did Inhibikase Therapeutics, Inc. beat estimates in Q4 2025?
- EPS beat the consensus estimate of $-0.12 by $0.03.
- How did Inhibikase Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 85.7% from $-0.63.
- Where can I find Inhibikase Therapeutics, Inc.'s Q4 2025 SEC filings?
- You can read the 8-K earnings release (0001193125-26-126322) and the 10-K periodic report (0001193125-26-126371) directly on SEC EDGAR. The filing index links above go to sec.gov.
